Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 06 - 28 tags : Positive save search
Medtronic InPen™ Real-World Data and Extended Infusion Set* Pivotal Trial Results Demonstrate Strong Clinical Outcomes and Positive User Experience
Published: 2021-06-28 (Crawled : 17:00) - biospace.com/
MDT | $79.3 -1.16% 2.4M
|
Health Technology
|
| O: 0.29%
H: 0.1%
C: -1.24%
positive trial trial results
Eiger BioPharmaceuticals Announces Presentation of Positive Phase 2 Results of Avexitide in Congenital Hyperinsulinism at the American Diabetes Association Virtual 81st Scientific Session
Published: 2021-06-28 (Crawled : 16:00) - biospace.com/
EIGR | $1.725 -1.45% 140K
|
Health Technology
|
| O: 4.84%
H: 5.28%
C: -1.65%
presentation diabetes phase 2 biopharma positive phase 2 results results insulin
MYM’s Acquisition by IMCC Receives Positive Recommendations from leading Independent Proxy Advisory Firms
Published: 2021-06-28 (Crawled : 14:00) - globenewswire.com
IMCC | $0.611 -15.93% -18.95% 600K
|
Manufacturing
|
| O: 2.56%
H: 3.27%
C: 3.27%
acquisition positive
Daré Bioscience Announces Positive Phase 1 Results for DARE-HRT1
Published: 2021-06-28 (Crawled : 12:15) - globenewswire.com
DARE | $0.48 -0.02% 48K
|
Health Technology
|
| O: 0.0%
H: 1.78%
C: -0.59%
phase 1 positive results phase 2 phase 3 bioscience
Hoth Therapeutics Announces Positive Safety Results from AD001 Cohort 1 of Phase 1b Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis
Published: 2021-06-28 (Crawled : 12:00) - ir.hoththerapeutics.com
HOTH | $1.18 -1.67% 35K
|
Health Technology
|
| O: 1.26%
H: 4.97%
C: -1.86%
treatment phase 1 positive results dermatitis trial atopic dermatitis phase 1b al001 adi-001 phase 2b
Kymera Therapeutics Announces Positive Interim Results from Single Ascending Dose Phase 1 Trial of KT-474 Demonstrating Degrader Proof-of-Mechanism
Published: 2021-06-28 (Crawled : 10:00) - globenewswire.com
SNY | $46.2 0.59% 210K
|
Health Technology
|
| O: 0.34%
H: 0.47%
C: 0.24%
KYMR | $34.57 0.52% 78K
|
Health Technology
|
| O: 2.97%
H: 3.46%
C: 3.24%
phase 1 positive results trial phase 2
Nirsevimab shows positive topline results in RSV Phase 2/3 MEDLEY trial
Published: 2021-06-28 (Crawled : 08:00) - biospace.com/
SNY | $46.2 0.59% 210K
|
Health Technology
|
| O: 0.34%
H: 0.47%
C: 0.24%
phase 2 phase 2/3 positive results topline trial
Gainers vs Losers
| 49% | 51% |
Top 10 Gainers
TPET | $0.503 117.66% 21M
|
n/a
WISA 4 | $3.22 84.0% 56M
|
Electronic Technology
SXTC | $2.56 82.86% 11M
|
Health Technology
PALI | $6.5 56.25% 22M
|
Manufacturing
JAGX | $0.1767 48.74% 430M
|
Health Technology
DYNT | $0.5255 41.87% 18M
|
Health Technology
PRSO | $1.79 40.95% 38M
|
Manufacturing
MCBC | $13.795 38.92% 820K
|
Finance
BTTR | $6.86 34.51% 5.2M
|
Manufacturing
SNGX | $0.51 32.09% 6.3M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.